President Donald Trump’s new prescription discount platform is officially online — and its first wave of savings is making a noticeable impact in one area often overlooked in federal health policy: women’s reproductive care.
TrumpRx, the administration’s long-anticipated drug coupon program, quietly launched earlier this month with discounts on 43 medications. Among them are four drugs commonly prescribed during in vitro fertilization (IVF) treatment — a move that aligns directly with Trump’s 2024 campaign pledge to expand access to fertility care.
While critics have characterized the rollout as modest, supporters say the inclusion of IVF medications marks a meaningful step for families struggling with the high cost of fertility treatment. IVF can cost up to $30,000 per cycle without insurance coverage, and although medications typically represent only a portion of that total — often 10% to 20% — the upfront price of fertility drugs alone can be a barrier for many couples.
Federal estimates indicate the program’s coupons could reduce costs by as much as $2,200 per IVF cycle. For patients undergoing multiple attempts — common given that each cycle carries roughly a 30% chance of resulting in pregnancy and live birth — even incremental savings can add up.
The platform also features discounts on GLP-1 medications often prescribed for obesity and diabetes, as well as certain treatments used for menopause. Observers note that the current list disproportionately includes medications that affect women’s health, a departure from many previous drug-cost conversations that centered largely on insulin and cardiovascular prescriptions.
TrumpRx operates similarly to established discount services. Patients can search medications on the site, then download a coupon to print or store digitally for use at participating pharmacies. The White House has said additional medications will be added over time.
Although the program does not address the full scope of IVF expenses — which include clinical procedures such as egg retrieval and laboratory work — fertility advocates acknowledge that lowering medication costs is a tangible starting point.
The initiative also enters a complex policy environment. Some conservative advocacy groups have raised ethical questions about IVF practices, while others within the administration have emphasized expanding family-building options. By including IVF-related medications in its first slate of discounts, the White House appears to be signaling support for fertility access, even as broader debates continue.
Alternatives to IVF, such as intrauterine insemination (IUI), are also part of the reproductive care landscape, but they carry their own considerations, including a higher likelihood of multiple pregnancies, which can increase medical risks.
For now, TrumpRx’s debut suggests that female-focused healthcare costs are receiving increased federal attention. While the program does not overhaul the economics of fertility treatment overnight, it represents a concrete policy action aimed at reducing one of the financial hurdles facing couples who want to grow their families.
More updates to the platform are expected in the months ahead, as the administration expands the list of discounted medications.
